Since αV integrins and VEGFR2 can be overexpressed on the surface of ovarian cancer cells, here we evaluated rationally designed dual conjugates characterized by the capability to both target αVβ3 integrin-expressing tumors and to inhibit VEGFR2. Here, KDR is linked to ovarian carcinoma.